Clinical Trial Update: Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 clinical trial updating the absolute bioavailability and mass balance of CHF6001 (tanimilast) in healthy subjects has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF6001 (tanimilast) (tanimilast)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Chronic Obstructive Pulmonary Disease (COPD), COPD | Phase 1 | Status: COMPLETED | Results posted: 2024-03-18